New drospirenone/17.beta.-estradiol regimen, pharmaceutical...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/585 (2006.01) A61K 31/565 (2006.01)

Patent

CA 2683093

The present invention relates to a pharmaceutical combination product with at least 21 daily consecutive dosage units containing from 2.0 mg to 3.0 mg of drospirenone and 1.0 to 2.0 mg of 17.beta.-estradiol in each daily dosage unit followed by intermittent daily dosage units containing the same or smaller amount of drospirenone (i.e. 0.5 mg to 3.0 mg) as the consecutive daily dosage units wherein each intermittent daily dosage unit is preceded by at least one day without administration of drospirenone. These pharmaceutical combination products can be used for female oral contraception, guarantee a withdrawal bleeding each 4 weeks and allow for the full maintenance of the drospirenone related benefits.

L'invention concerne un produit de combinaison pharmaceutique à au moins 21 unités de dosage consécutives quotidiennes contenant 2,0 mg à 3,0 mg de drospirénone et 1,0 à 2,0 mg de 17 .beta.-oestradiol dans chaque unité de dosage quotidienne suivies d'unités de dosage quotidiennes intermittentes contenant la même quantité ou une quantité moindre de drospirénone (soit 0,5 mg à 3,0 mg) que les unités de dosage quotidiennes consécutives, chaque unité de dosage intermittente étant précédée par au moins un jour sans administration de drospirénone. Ces produits de combinaison pharmaceutique peuvent être utilisés pour la contraception féminine par voie orale, garantissent une hémorragie de privation toutes les quatre semaines et permettent une pleine conservation des avantages relatifs à la drospirénone.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

New drospirenone/17.beta.-estradiol regimen, pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with New drospirenone/17.beta.-estradiol regimen, pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and New drospirenone/17.beta.-estradiol regimen, pharmaceutical... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2013358

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.